Immune profiling of stage III non-small cell lung cancer patients treated with concurrent chemoradiation and adjuvant durvalumab: A prospective observational phase II trial
- Conditions
- immune changesnon-small cell lung cancer1003866610029107
- Registration Number
- NL-OMON52550
- Lead Sponsor
- MAASTRO clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 120
• Pathological diagnosis of adequately staged (according to standard practice
using chest-CT, FDG-PET, brain imaging MRI/CT) NSCLC
• Participant is willing and able to give informed consent for participation in
the trial
• Male or female, aged 18 years or above
• Scheduled to receive one of the following two therapeutic strategies:
o Concurrent chemotherapy and radiotherapy with photons (60 Gy in 30 fractions
of 2 Gy) in patients with stage III NSCLC
o Concurrent chemotherapy and radiotherapy with protons (60 Gy in 30 fractions
of 2 Gy) in patients with stage III NSCLC
• Is able and willing to comply with all trial requirement
• Mixed non-small cell lung cancer with other histologies such as small cell
lung cancer
• Not able to comply with the study protocol
• Less than 18 years* old
• Pregnancy or not able to comply with adequate contraception in women with
child baring potential
• Previous radiotherapy to the chest for benign or malignant conditions,
including radiation for breast cancer
• Previous malignancy treated with chemotherapy, immune therapy or radiotherapy
(irrespective of when this happened)
• Previous malignancies treated with surgery only are allowed if 2 years or
more before inclusion in the present study
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method